|
|
|
| Webinar: Flexible Therapeutic Development: Balancing Speed, Cost, and Process | Behind every molecule is a unique development strategy. In this webinar, KBI Biopharma showcases its flexible microbial protein platforms designed to accelerate first-in-human programs with speed, cost-efficiency, and process robustness. Explore considerations in cell line development, fermentation, and purification, and learn how platform-based approaches and robotic workflows align milestones from proof-of-concept through toxicology material generation with no license fee to evaluate. Click here to learn more. |
|
|
|
| A Unified Strategy For E&L Risk Mitigation | Article | By Vicki Ward, Ph.D., Pace Life Sciences | A practical USP <1665> and <665> framework helps manufacturers evaluate and manage extractables and leachables risk, supporting quality, safety, and regulatory compliance. |
|
|
|
|
|
|
By Jeffrey S. Buguliskis, Ph.D., deputy chief editor, Outsourced Pharma | Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
| The Science Of Cell Line Development For Biologics | Article | By Palak Patel, Thermo Fisher Scientific | Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success. |
|
|
|
|
|
| Navigating The 'Now What' After Early-Phase Success | Article | By Jeffrey O’Connor, Lonza | While moving from early- to late-phase clinical trials is a critical milestone to celebrate on the way to commercialization, many face the same daunting question once the confetti settles ― now what? |
|
|
|
|
| Webinar: Enhanced biotherapeutic protein expression using advanced vector systems | In recombinant protein manufacturing with GS-CHO cells, vector design at transfection sets the stage for titre, quality, and long-term stability. In this webinar, Lonza introduces GSquad® Pro, its next-generation expression vector platform featuring the high-performance LHP-1 promoter. Discover how data-driven insights into gene expression control are advancing CHO vector design, accelerating development timelines, and strengthening key biomanufacturing performance metrics. Click here to learn more. |
|
|
|
Latest Developments In Fill/Finish | Argonaut Manufacturing Services | Leverage advanced isolator-based fill-finish capabilities to achieve precise, efficient, and flexible sterile manufacturing for biologics, small molecules, vaccines, and other complex formulations.. |
|
|
Our Spokane Foreign Trade Zone (FTZ) | Jubilant HollisterStier | Foreign Trade Zones help businesses cut costs and improve efficiency by deferring or eliminating tariffs, streamlining imports, and enabling faster market access while maintaining flexibility for global distribution. |
|
|
Biologics Discovery Capabilities | Curia | Accelerate your biologics program with an integrated discovery‑to‑development partner built to deliver high‑quality candidates with speed and scientific rigor. |
|
|
Consistent, Reliable, High-Quality Components | West Pharmaceutical Services, Inc. | See a premium line of components for vials, prefilled syringes, and cartridge systems developed and refined to provide best-in-class levels of quality, performance, and risk mitigation. |
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
